IP Library Granted Patent US 9,795,580
Granted Patent B2
US 9,795,580 · App. 15/163,194 · Granted Oct 24, 2017

Ketone supplements for treatment of angelman syndrome

Inventors: Edwin John Weeber (Apollo Beach, FL); Stephanie Lynn Ciarlone (Bassett, VA); Dominic Paul D'Agostino (Tampa, FL)
Assignee: UNIVERSITY OF SOUTH FLORIDA
A61K31/22A61K31/19A61K31/225
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,795,580
App. No.
15/163,194
Granted
Oct 24, 2017
Kind
B2
Abstract

The invention concerns a method of treating Angelman Syndrome (AS) in a subject, comprising inducing ketosis in the subject by administering a therapeutically effective amount of a ketone ester, such as an R,S-1,3-butanediol acetoacetate ester, wherein administration of the ketone ester elevates the blood ketone level in the subject. Other aspects of the invention include a method of increasing cognitive function and/or motor function in a subject with AS; and a method of decreasing seizures and increasing the latency to seize in a subject with AS.

Claims (15)

1. A method of treating Angelman Syndrome (AS) in a subject, comprising inducing ketosis in the subject by administering a ketone supplement to the subject.

2. The method of claim 1 , wherein the ketone supplement comprises β-hydroxybutyrate (BHB) salt.

3. The method of claim 2 , wherein the ketone supplement comprises a mixture of the BHB salt and a medium chain triglyceride (MCT).

4. The method of claim 2 , wherein the BHB salt is a sodium/calcium BHB salt.

5. The method of claim 1 , wherein the ketone supplement comprises a ketone ester.

6. A method of increasing cognitive function and/or motor function in a subject with Angelman Syndrome (AS), comprising inducing ketosis in the subject by administering a ketone supplement to the subject.

7. The method of claim 6 , wherein the ketone supplement comprises β-hydroxybutyrate (BHB) salt.

8. The method of claim 7 , wherein the ketone supplement comprises a mixture of the BHB salt and a medium chain triglyceride (MCT).

9. The method of claim 7 , wherein the BHB salt is a sodium/calcium BHB salt.

10. The method of claim 6 , wherein the ketone supplement comprises a ketone ester.

11. A method of decreasing seizures, increasing the latency to seize, and/or increasing the ratio of hippocampal gamma-amino butyric acid (GABA) to glutamate in a subject with Angelman Syndrome (AS), comprising inducing ketosis in the subject by administering a ketone supplement to the subject.

12. The method of claim 11 , wherein the ketone supplement comprises β-hydroxybutyrate (BHB) salt.

13. The method of claim 12 , wherein the ketone supplement comprises a mixture of the BHB salt and a medium chain triglyceride (MCT).

14. The method of claim 13 , wherein the BHB salt is a sodium/calcium BHB salt.

15. The method of claim 11 , wherein the ketone supplement comprises a ketone ester.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2017
From: WEEBER, EDWIN JOHN; CIARLONE, STEPHANIE LYNN; D'AGOSTINO, DOMINIC PAUL
To: UNIVERSITY OF SOUTH FLORIDA
Reel/Frame 043221/0037 →
Continuity (2)
Continuation 14755358 · Jun 30, 2015
Related Publication 20170000754A1 · Jan 5, 2017